FIELD: chemistry.
SUBSTANCE: invention relates to a method of treating or preventing, suppressing or ameliorating type 2 diabetes and/or diseases, disorders and conditions of low glucose tolerance, insulin resistance and / or hyperglycemia associated with type 2 diabetes in a subject in need thereof, comprising administering to said subject a therapeutically or prophylactically effective amount of a compound of formula IIIg or pharmaceutically acceptable salts and / or stereoisomers thereof, preferably compounds of formulae IIIi1 and IIIi2: 
IIIg 
III1 III2 in which R1 means H, -ORa; R2 means H or halogen; R4, R5, independently of each other, mean H, -ORa, where Ra is H; R2’ means H; L means C(1-6)straight or branched chain alkyl; X means -COORc; Rc means H or C(1-6)alkyl; m is from 0 to 5.
EFFECT: technical result is an effective method for the treatment of type 2 diabetes with compounds of formula IIIg.
9 cl, 5 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
| TRICYCLIC CONDENSED DERIVATIVES OF PYRIDIN-2-ONE AND USE THEREOF AS BRD4 INHIBITORS | 2016 |
|
RU2734959C2 |
| NOVEL HETEROCYCLIC COMPOUNDS AS BRD4 INHIBITORS | 2016 |
|
RU2721120C2 |
| NEW OXIME CHOLEST-4-EN-3-ONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHOD FOR PREPARING | 2009 |
|
RU2496784C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
| DEUTERATED DERIVATIVE OF CHENODEOXYCHOLIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND | 2016 |
|
RU2712033C2 |
| OBESITY TREATMENT | 2019 |
|
RU2822679C2 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
| N4-PHENYLQUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS RECEPTOR TYROSINE KINASE TYPE ERBB INIHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | 2006 |
|
RU2428421C2 |
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
